• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

Spiramycin Hexanedioate

Product ID S6233
Cas No. 11034-40-5
Purity ≥90%
Product Unit SizeCostQuantityStock
1 g $122.50 In stock
5 g $368.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Spiramycin is a macrolide antibiotic that is clinically used to treat toxoplasmosis and other soft tissue infections. Spiramycin exhibits antibacterial efficacy against Toxoplasma, inhibiting bacterial protein synthesis. In vitro, spiramycin decreases levels of IL-10 and TNF-α, and in vivo, it decreases Toxoplasma-induced brain cysts.

Product Info

Cas No.

11034-40-5

Purity

≥90%

Synonym

Spiramycin Adipate, stomamycin, suanovil

Solubility

Soluble in most organic solvents.

Appearance

Slightly yellowish or white powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

S6233 MSDS PDF

Info Sheet

S6233 Info Sheet PDF

References

Calcagnile M, Jeguirim I, Tredici S, et al. Spiramycin disarms Pseudomonas aeruginosa without inhibiting growth. Antibiotics (Basel). 2023 Mar 2;12(3):499. PMID: 36978366.

Kang J, Kang H, Hyun C. Anti-inflammatory effects of spiramycin in LPS-activated RAW 264.7 macrophages. Molecules. 2022 May 17;27(10):3202. PMID: 35630676.

Omar M, Abaza B, Mousa E, et al. Effect of spiramycin versus aminoguanidine and their combined use in experimental toxoplasmosis. J Parasit Dis. 2021 Dec;45(4):1014-1025. PMID: 34789985.

Kieffer F, Wallon M. Congenital toxoplasmosis. Handb Clin Neurol. 2013;112:1099-101. PMID: 23622316.

Büyükbaba Boral O, Sönmez Tamer G, Keçeli Özcan S, et al. Investigation of combined effectiveness of spiramycin and beta-glucan in mice models of acute toxoplasmosis and determination of IL-10, IL-12 and TNF-α levels. Mikrobiyol Bul. 2012 Jul;46(3):446-55. PMID: 22951656.

Chew WK, Segarra I, Ambu S, et al. Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis. Antimicrob Agents Chemother. 2012 Apr;56(4):1762-8. PMID: 22271863.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only